Şunu aradınız:: ag (İngilizce - İzlandaca)

ag
unit description in lists

anti-hbs ag
gegn-hbs ag

1,5-ag assay
1,5-ag greining

attogram; attograms; ag
amount in units (real)

manufacturer baxter ag industriestrasse 67
framleiðandi baxter ag industriestrasse 67

lonza ag lonzastrasse 3930 visp switzerland
lonza ag lonzastrasse 3930 visp sviss

anti-hbs ag (≥ 10 miu/ml)b
gegn-hbs ag (≥ 10 iu/ml)b

roche pharma ag emil-barell-str.
roche pharma ag emil-barrell-str.

csl behring ag wankdorfstrasse 10, 3000 bern 22 switzerland
csl behring ag wankdorfstrasse 10, 3000 bern 22 sviss

baxter ag industriestrasse 67 a-1221 vienna austria
baxter ag industriestrasse, 67 a-1221 vienna austurríki

manufacturer roche pharma ag emil-barell-str.
framleiðandi roche pharma ag emil-barrell-str.

roche pharma ag, emil-barell-strasse 1,
roche pharma ag, emil-barrel-strasse 1,

name and address of the manufacturer responsible for batch release bayer pharma ag
heiti og heimilisfang framleiðenda sem eru ábyrgir fyrir lokasamþykkt

hexal ag, industriestrasse 25, d-83607 holzkirchen, germany
hexal ag, industriestrasse 25, d-83607 holzkirchen, Þýskaland

lungomare pirandello, 8 92014 porto empedocle (ag) italy
lungomare pirandello, 8 92014 porto empedocle (ag) ÍtalÍa

if you have any questions about kogenate bayer and compatible separate filters contact bayer pharma ag.
vakni einhverjar spurningar um kogenate bayer og stakar hentugar síur hafið samband við bayer pharma ag.

for further detail, it may be advisable to contact the specific manufacturer of the 1,5-ag assay.
fyrir frekari upplýsingar er ráðlegt að hafa samband við framleiðanda 1,5-ag greiningarprófsins.

therefore, 1,5-ag assays should not be used for assessment of glycemic control in patients on canagliflozin.
Því á ekki að nota 1,5-ag greiningu til að meta blóðsykursstjórnun sjúklinga sem nota kanaglíflózín.

name and address of the manufacturer(s) of the biological active substance(s) lonza ag
heiti og heimilisfang framleiðenda líffræðilegra virkra efna lonza ag

efavirenz demonstrated antiviral activity against most non-clade b isolates (subtypes a, ae, ag, c, d, f, g, j, and n) but had reduced antiviral activity against group o viruses.
sýnt var fram á andveiruvirkni efavírenz gegn flestum utan greina (non- clade) b stofnum (undirgerðir a, ae, ag, c, d, f, g, j og g), en minni andveiruvirkni gegn veirum af o- stofni.